Please ensure Javascript is enabled for purposes of website accessibility

Valeant Receives Antitrust Clearance for Obagi Purchase

By Rich Duprey - Apr 22, 2013 at 4:44PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Transaction still requires approval of Ukranian antimonopoly regulators.

The waiting period for Valeant Pharmaceuticals(BHC -9.79%) acquisition of Obagi Medical  Products  (NASDAQ: OMPI) under the Hart-Scott-Rodino Antitrust Improvements Act, or HSR, expired on April 19, the company announced today, allowing the transaction to move to the next phase. 

Valeant offered to buy Obagi for $19.75 a share on March 20. A subsequent bid by Merz Pharma for $22 a share led Valeant to raise its offer earlier this month to $24 a share, or $417 million.

The HSR requires merging companies to file detailed reports with the FTC and the Justice Department to see whether the combination violates antitrust laws. There is a 30-day waiting period (15 days for all-cash transactions) before the merger can be completed. The companies can request the waiting period be terminated early, which will be granted if both antitrust agencies complete their reviews and determine that no enforcement action is necessary.

The completion of the tender offer is also conditioned on approval of the Antimonopoly Committee of Ukraine for purposes of compliance with applicable Ukrainian antimonopoly law. Although there can be no guarantee or assurance, Valeant believes it is possible that the parties may receive approval from the committee in the near future. 

Valeant also requires the tender of a majority of the outstanding shares of common stock of Obagi, which it expects to complete promptly after the committee's approval.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bausch Health Companies Inc. Stock Quote
Bausch Health Companies Inc.
$9.95 (-9.79%) $-1.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.